

Index

a

- abbreviated new drug application (ANDA) 256, 660–661, 696
- ABC transporters 183, 184
- Abraxane[®] 298
- absorption, distribution, metabolism and excretion (ADME) 3, 32, 305, 468
- acid dissociation constant (pK_a) 177
- AC88 nanosuspension 295, 296
- acquired immune deficiency syndrome (AIDS) 257
- action potential duration (APD) 537
- active pharmaceutical ingredient (API) 125
 - ancillary expenses
 - analytical considerations 65
 - API advance development 66–68
 - cGMP surcharges 66
 - long term consideration 69
 - polymorph screening and salt screening 65–66
 - anhydrate 204, 205
 - chromatographies cost 63
 - CoG estimation 59
 - core functions
 - palladium-catalyzed Suzuki–Miyaura cross-coupling reaction 17
 - partner functions 16, 25
 - process safety function 19
 - crystalline form 204
 - crystallization 19
 - discovery to development, transition 14–16
 - DPI 219
 - drug filing pathway 12
 - early development drivers and constraints 12
 - guidelines 243
 - hydrate 205
 - initial CoG projections 55
 - particle size and crystallinity 218, 308
 - physicochemical properties 213, 306
 - POC 15
 - polymorphism 206
 - preparative chromatography 53
 - process development equipment 229
 - cGMP manufacturing equipment 27
 - lab equipment 25
 - NMR 25
 - PXRD 26
 - scale-up equipment, laboratory 26
 - UPLC 25
 - raw material consideration 53, 63
 - Reg–Tox 12
 - research stages 50
 - specialized technology groups 21
 - spray drying process 213
 - synthetic route translatability and scalability 52, 58, 159
- active pharmaceutical ingredient drug substance (API DS) 49, 52, 57
- adverse outcome pathways (AOPs) 581
- aerodynamic particle size 278
- 1,3-alkoxy-pyrrolidines 583

- ALK^{WT} model 442–449, 456, 457, 459
- α -isopropylpropanoyloxymethyl ester 33
- α -methyl cinnamates 96
- American Chemical Society Green Chemistry Institute
Pharmaceutical Roundtable (ACS GCIPR) 81
- American Intellectual Property Law Association 738
- American Type Culture Collection (ATCC) 739–742
- amlodipine besylate 252, 253
- amorphous drug nanoparticles 335, 360
- amorphous nanosuspensions
 exposure vs. crystalline suspensions 356–358
 lead optimization 358–360
 melt emulsion method 342
 Ostwald ripening inhibitor 342
 polyvinylpyrrolidone (PVP) 341
 precipitation method 341
 SDS 341
- amorphous solid dispersion (ASD)
 defined 213
 dissolution and stability issue 214–215
 drug product 213
 HME 214
 spray drying 213–214
 workflow 214
- anaplastic lymphoma kinase (ALK) 441, 443–445, 447, 452, 453
- angiotensin converting enzyme (ACE) inhibitor 33, 185
- anhydrate 204–206, 210, 211, 240, 241, 252–254
- anipragliflozin 230
- antibacterials
 drug-resistant strains 484
 translational PKPD model
 BL/BLI combinations 484
 predict clinical efficacy 486–487
 semi-mechanistic model 484–486
- anti-inflammation 489–491
- anti-lipolysis 373
- apical membrane 181, 182, 184
- apical-to basolateral (A-B) 353, 402, 413
- aromatic heterocycles 79, 93
- artificial neural networks (ANN) 553, 556–557
- artificial stomach duodenal model (ASD) 311
- aryl hydrocarbon receptor (AhR) 607–609
- asymmetric hydrogenation 93, 96, 97, 103
- Atorvastatin (CI-981) 258
- Avista Pharma Solutions 47
- Avogadro's number (N_A) 181
- azidation/oxygenation sequence 155
- 4'-azido-2'- β -methyl-2'-desoxycytosine, synthesis
 dehydration and hydration 155
 process safety 161
- 4'-azido-2'-deoxy-2'-C-methylcytidine 145
- 4'-azido-2'-methyl-2'-desoxycytosine 164
- b**
- Bacillus megaterium* 84
- Bacillus subtilis* 87
- BA99 nanosuspension 295, 296
- basolateral membrane 181, 182, 185
- benchmark dose (BMD) approach 551, 591
- benzo(a)pyrene 611, 612
- benzyltriethylammonium azide 156
- β -lactamase inhibitors (BLIs) 484
- β -lactam-containing (BL) antibacterials 483
- β -naphthoflavone (BNF) 607, 608
- bile salts 178, 186, 291
- binding arbitration 736
- bioavailability/bioequivalence (BA/BE) 172
- biocatalysis 22, 73–76, 78–82, 87, 89, 90, 113
- biohydroxylation of α -isophorone 84
- biopharmaceutical approach 179

- Biopharmaceutics Classification System (BCS) 5, 172, 212, 290, 333
- biosimilars 49, 697
- bis(acetoxy)iodobenzene (BAIB)
oxidation 152
- black-box deconvolution 374
- bovine serum albumin (BSA) 81
- Brintellix[®] 125, 126
- Bristol–Myers Squibb (BMS) IND initiative
enthusiasm 40
optimization 39
parallel activities 38
teamwork 40
- C**
- Caco-2 A–B permeability 413
- Caco-2 cell assay⁹ 356, 401
- Caco-2 cell model 353
- Cambridge Structural Database (CSD) 205, 238
- Capsugel Xcelodose[®] 313
- carboxylic acid reductases (CARs) 87
- Cardiac Safety Research Consortium (CSRC) 543
- cardiovascular (CV) system
cardiac action potential 538–539
chemical or pharmacological class 538
heart muscle 536
ICH S7A 536
I_{kr} (hERG) Inhibition 538
in vivo assessments 539
respiratory system 540
supplemental safety pharmacology
gastrointestinal system 541
renal 541
surface ECG represents 536, 537
- cascade biotransformations 86–89
- Catalent, Inc. 47
- catalytic reactions 21, 22, 95, 99
- Center for Drug Evaluation and Research (CDER) 549
- central nervous system (CNS) 472, 503, 527, 534–535
- certificates of analysis (COA) 67
- C-4' functionalization 155–158
- Chan–Lam coupling 94
- chemical catalysis 75–103
- chemical complexity, BMS 42–43
- chemical transformation 58, 74, 109, 113
- cheminformatics 549, 552
- Chemistry, Manufacturing, and Controls (CMC) 11, 277
- chemocatalytic oxidation methods 83
- chiral 2-aryl piperidines 87
- chromatography 13, 18, 25, 27, 46, 53–55, 59, 60, 62, 63, 65, 146, 163, 164, 240, 283, 346
- clearance (CL)
hepatic biliary 406–407
hepatic metabolic
in vitro based prediction 403–405
in vivo data 405–406
renal plasma 407–408
scaling of 408–410
- cleaved caspase-8 (CC8) 632
- clinical trial application (CTA) 207
- cocrystal conformer (CCF) 248
- Code of Federal Regulations (CFR) 27, 255
- coformers 230–236, 238, 240, 247, 249, 250, 253
- colchicine 184, 587, 588, 591, 592, 661, 662
- compound safety assessment
biotransformation and reactive metabolites 506–507
cytotoxicity 505
genetic toxicology 509–510
genotoxic impurities 510–511
mitochondrial toxicity 505–506
MTD/DRF 512–513
phototoxicity 508–509
preclinical efficacy and PK study 511–512
safety pharmacology 512
secondary pharmacology 507–508
- comprehensive *in vitro* proarrhythmia assay (CiPA) 544
- connectivity map (CMAP) 582, 591
- constitutive androstane receptor (CAR) 607

- continuous chemistry 73–75, 103–111
 continuous stirred tank reactors (CSTRs) 27
 contract development and manufacturing organization (CDMO) 47, 55
 contract manufacturing organizations (CMOs) 11, 16, 20, 21, 23, 31, 42, 48, 55, 110
 contract research organization (CRO) 11, 31, 45–48, 55, 509, 730
 contract research organization/contract manufacturing organization (CRO/CMO) 55
 Copyright and Patent Agreement (CPA) 733
 COSMO-RS software 307
 cost of goods (CoG)
 vs. campaign time cycle 56
 contribution 67
 factors 49
 vs. time cycle 57
 counterions 229–237, 240, 242, 243, 247, 249, 255, 257, 283
 Court of Justice of the European Union (CJEU) 718
 Crestor™ 695, 696
 critical micelle concentration (CMC) 11, 24, 36, 38, 39, 47–48, 178, 186
 crizotinib
 ALK-and MET-studies 439
 case study
 ALK 441, 442
 clinical phase I dose-escalation 441
 MET 441
 nonclinical tumor study 442–443
 PK analysis 443–444
 PKDZ relationships 446
 PK-PDDZ understanding 437, 446–449
 PKPD relationships 444–446
 translational pharmacology 449–451
 Naïve-pooled PK analyses 438
 nonclinical studies 437
 Crohn's disease 184
 crystalline drug nanoparticles 346–351, 360
 crystalline salts 159, 229, 241
 crystallization protocol 19, 46, 67
 current Good Manufacturing Practices (cGMP) 14
 current state biocatalysis 78–82
 cyclodextrin-based formulations 186, 337
 cyclopropanation reactions 85
 cyclopropylcarbiny/cyclobutyl/homoallyl cation system 31
 cytochrome p450 enzymes (CYPs) 401, 606, 607, 613
 cytotoxicity 505, 635
- d**
- Dalton Pharma Services 47
 data integration 489, 582, 591–592
 death-inducing signaling complex (DISC) 632
 death receptor 4 (DR4/TRAIL-R1) 631
 decision trees 244, 276, 306, 326, 552–554, 558
 Declaration of Helsinki 315, 527
 decomplexation 126, 128, 129
 decoy receptor 2 (DcR2 or TRAIL-R4) 631–632
 dehydration 149, 154–155
 deprotection reactions 78
 Derek Nexus's approach 557, 558, 561
 design–make–test cycles 499, 513
 Design of experiments (DOE) 22, 75, 236, 369
 desired particle size 207, 214, 276, 290–294
 developability classification system (DCS) 325
 diabetes
 evolution of pharmacology experiments 476–478
 GDIS 476
 GPR40 agonist MK-8666 480–483
 GPR40 receptor agonists 476
 in vivo EC₅₀ value 480
 PKPD model development 479–480
 diastereoselective reduction 153

- diastereoselectivity 83, 85, 87, 101, 149, 154
 - diester prodrugs 145
 - differential scanning calorimetry (DSC) 19, 156, 161, 240, 340
 - discovery-development transition
 - ADME 32
 - in 1980 33–34
 - in 1990 34–40
 - SHR 32
 - Disperse Orange 37, 204
 - di-*t*-butylphosphiniferrocene (dtpf) 154
 - dose-limiting toxicities (DLTs) 207, 449
 - dose number 173–177, 314, 315, 318–322, 324, 325
 - dose predictions 370, 374, 400–401, 418, 422–425, 472, 477, 478, 605, 620
 - dose range finding (DRF) 502, 512–513
 - drug development process 468, 705
 - drug discovery
 - of APIs 66–68
 - cytotoxicity 505
 - fields of safety sciences 585
 - integration of pharmacokinetic and pharmacodynamic 367–396
 - in silico* PBPK models 569
 - in vitro* and *in silico* strategies 305
 - modern tools 171
 - pharmacological properties 530
 - phases of 434, 581, 594
 - drug dissolution 176, 179
 - drug-drug interactions (DDI) 399, 416, 605, 613
 - drug formulation development 680
 - drug metabolism and pharmacokinetics (DMPK) 367, 603–627
 - drug nanosuspensions
 - amorphous and crystalline 335, 339
 - case study 356–358
 - in vivo* dose decisions
 - chemical stability 352
 - colloidal stability 352
 - dissolution rate measurement 351–352
 - parenteral administration 352
 - solubility measurements 350–351
 - manufacturing method
 - melt emulsion method 344–346
 - precipitation method 343–344
 - ultrasonic crystallization method 346–347
 - wet milling method 348–350
 - microsuspensions 339
 - milled nanocrystals 352–355
 - pH-solubility profile 334
 - reasons 339
 - selection of stabilisers 340
 - solutions
 - cosolvents 337
 - cyclodextrins 337
 - pH-adjustment 336
 - surfactants 337–338
 - Drug Price Competition and Patent Term Restoration Act 658, 673, 696
 - drug substance
 - particle habit 215–219
 - particle size 219–221
 - drug toxicity development program 501–502
 - dry powder inhalation (DPI) 219
- e**
- early drug development
 - formulation selection, FiH 312
 - industrial assessments
 - commercial software and non-commercial models 560
 - confusion matrix 560
 - predictive computational toxicology tools 559, 565
 - predictive metrics 566
 - predictive toxicology models 567
 - multidisciplinary process 1
 - preclinical formulation selection
 - ASD model 311
 - compendial dissolution methods 309
 - D–P systems 311

- early drug development (*contd.*)
- gastrointestinal environment 309
 - principles and technology 305
 - Sirius Inform™ equipment 310
- predictive model
- fit a well-defined model 552
 - genetic toxicity 552
 - knowledge-based methods 557
 - machine learning algorithms 552
- predictive toxicology 550
- regulatory perspectives 567
- TK/TD 6
- TPP 2, 3
- Elbasvir, synthesis of 102, 108
- electrocyclization reaction 97
- Emend® 298
- enantiomeric enzymes 80
- enantioselective alkenoic acid
- hydrogenation 96
- enforcement costs 738–739
- ensembles of models 553–555
- environmental, health and safety (EHS)
- factors 52
- epoxide hydrolase (Ephx) genes 607, 608
- ertugliflozin:pyroglutamic acid cocrystal 229
- ester/amide/carbamate protection 78
- etoposide's theoretical permeability 187
- Eurasian Patent Office 704
- European Generic Medicines Association 709
- European Medicines Agency (EMA) 125, 174, 256, 528
- European Patent Convention (EPC) 650, 685
- European patent law 652–654
- European Patent Office (EPO) 669, 670, 685, 704
- evergreening 709, 710
- extemporaneously prepared (EP)
- formulations 313
- f**
- Fas-associated death domain (FADD) protein 632
- fasted simulated intestinal fluid (FaSSIF) 252, 253, 315
- FDA Critical Path regulatory science 568
- FDA's Critical Path Initiative 568
- FDA's Critical Path Opportunities for Generic Drugs 569
- felodipine 343, 351
- fenofibrate formulation developments 298
- fermentation technology 76
- Fick's law 171, 181
- finalize our raw material (FORM) team 38
- first-in-human (FiH)
- clinical studies 15
 - extemporaneously prepared (EP) PIC formulation
 - advantages 313
 - clinical data analysis methodology 315
 - clinical doses 320
 - clinical performance 314
 - clinical success for 320
 - permeability values 318
 - physicochemical characteristics 318
 - solubility values 318
 - supply 12
- first vs. second generation drugs 674
- fit-for-purpose (FFP) 7, 19, 52, 207, 230, 294, 296, 313, 314, 327, 340, 348, 438, 492, 519
- fluorescence imaging plate reader (FLIPR) assay 478
- fluoxetine hydrochloride 110, 111, 240, 252
- focused beam reflectance measurement (FBRM) 25, 279
- form selection process 204, 206, 212
- Freedom to Operate (FTO) analysis 4, 96, 727
- free drug hypothesis 378, 379, 435, 450
- front-loading process safety 56
- fumaric acid cocrystal 252
- functional observation battery (FOB) 534

g

gastroesophageal reflux disease (GERD) 352
 gastrointestinal tract (GIT) 171, 356
 GastroPlus™ 179, 291, 310, 353
 generally recognized as safe (GRAS) 217
 generic companies, strategies
 drugs and commercial manufacturing process 713
 goal 703
 marketing authorisation 713
 patent expiry and regulatory data 712
 generic drugs 6, 174, 501, 658–663, 666, 673, 692, 694–696, 698, 699, 702–704, 712, 714, 716, 724, 725
 genetic toxicity testing 589
 genetic toxicology 509–510, 571
 genotoxic impurities (GI) 11, 17, 24, 39, 41, 161–163, 247, 510–511, 560, 567
 Gibbs–Kelvin–Kohler equations 290
 Gilenya® 603
 glucose dehydrogenase (GDH) 83
 glucose-dependent insulin secretion (GDIS) 476, 481
 glucose tolerance test (GTT) 476, 477
 good laboratory practice (GLP) 12, 38, 246, 399, 509, 534, 539, 638–639
 Good Manufacturing Practice (GMP) 14, 207, 246
 Goto-Kakizaki (GK) rat 477
 Gram-negative bacteria 483–485
 Grignard reagent 17, 91

h

halogenated aromatic hydrocarbons (HAHs) 611
 Hatch–Waxman Act 257, 658–663, 666, 673, 696, 725
 Health's Developmental Therapeutics Program (DTP) 554
 hepatic biliary clearance 406–407
 hepatic blood clearance 404, 413
 hepatic metabolic clearance
 in vitro based prediction 403–405

in vivo data 405–406
 hepatocarcinoma cells (HepG2) 584
 heteroatom arylation 90
 heterosynthons 232, 234
 high content imaging
 automated microscopy 585
 microtubuline aggregates 586
 U2OS 585
 high-pressure homogenization (HPH) 221, 274, 275, 345, 359, 360
 high-throughput experimentation (HTE) 21, 94, 95, 97, 101
 high-throughput screening (HTS) 21, 78, 101, 207, 211, 231, 236, 305, 581
 homosynthons 232
 hot melt extrusion (HME) 110, 213, 214, 249, 291
 human ether-a-go-go related gene (hERG) 507
 human immunodeficiency virus (HIV) infection 257
 human MK-1 dose vs. TE relationship prediction 475
 human PKPD predictions
 exposure target 416
 fundamental principles for
 analyses of 421
 compound-related properties 417
 discovery process 418
 pharmacokinetics 419
 preclinical 422
 system properties 417
 target engagement/mechanistic biomarker 421
 target engagement/modulation 419
 target modulation/engagement 418
 human prostate cancer cells (LNCaP) 584
 human tumor xenograft models 434, 442
 hydrates 66, 204–206, 210–212, 217, 236, 240, 241, 243, 252–254, 256
 hydration 204, 252

- hydrazoic acid (HN₃) formation 158
 hydroxypropyl methylcellulose (HPMC)
 217, 249–251
- i**
- imine reductase (IRED) 83
 immediate-release (IR) product 172
 indemnification 739
 indinavir sulfate 236, 254, 257
 indirect response model 421, 438, 439,
 441, 444, 454, 455
 inflammatory bowel disease (IBD) 603
 inhibitor of apoptosis proteins (IAP)
 633
 innovator
 drugs approval 705
 drug value 704
 inositol phosphatase 1 (IP1)
 accumulation assay 478
 in-process control (IPC) 23, 65, 149
in silico process modeling tools 19
in silico toxicology 551
in situ product recovery (ISPR)
 method 87
 intellectual property (IP)
 copyrights 724
 injunctions 703
 paragraph IV issues 697
 patent system 722
 position 716
 trademark 724
 trade secret 724
 Intellectual Property Appellate Board
 (IPAB) 723
 internal corporate strategy 705
 International Conference on
 Harmonisation (ICH) 27, 205,
 529
 International Conference on
 Harmonization (ICH) Q11 256
 International Congress on Harmoni-
 zation (ICH) guidelines 7
 International Council for Harmoni-
 zation for Pharmaceuticals for
 Human Use (ICH) 17
 International Trademark Association
 724
- intramolecular C–H functionalization
 97, 99
 investigational medicinal product
 dossiers (IMPDs) 24
 investigational new drug (IND) 24,
 207, 657
 iodoazidation reaction 156
 iron-catalyzed Kumada reaction 17
 iron-mediated synthetic route 126,
 128–130, 132, 141
- j**
- Japanese Guidance for Nonclinical
 Studies of Drugs Manual 528
- k**
- ketoreductase (KRED) 22, 82
 Kilogram Laboratory (Kilo Lab)
 equipment 12
 k-nearest neighbors (k-NN) 553,
 555–556
 knowledge-based methods 556–558
- l**
- lead identification phase 335
 lead optimization, PDE10A inhibitors
 581–598
 leveraging preclinical animal studies
 impact on normal tissue 637–638
 vulnerable tumor types 637
 Levich variations 176
 lifecycle management 252, 255, 258,
 297, 301
 Lipitor™ 258, 696, 697
 lipophilic drugs 178, 182, 185–188,
 292, 604
 liquid chromatography–mass
 spectrometry (LCMS) 65
 litigations
 participation in 742–743
 patents enforcement 744
 lorlatinib
 ATP-binding mechanism 440
 case study
 EML4-ALK^{L1196M} 451
 nonclinical Study 452
 PK analysis 452–453

- PKDZ relationships 454–456
 - PK-PDDZ understanding
 - 456–457
 - PKPD relationships 453–454
 - translational pharmacology
 - 457–459
 - Naïve-pooled PK analyses 438
 - PKPD model 439–440
 - lowest benchmark dose level (BMDL)
 - 551
 - lymphocytes 603, 604, 625, 632
 - Lyricea™ 110, 695
- m**
- machine learning algorithms
 - ANN 556–557
 - decision trees 553
 - ensembles of models 553–555
 - k-nearest neighbors (k-NN)
 - 555–556
 - Naïve Bayes' classification 556
 - Madin–Darby canine Kidney cell line (MDCK) 401
 - major depressive disorder (MDD) 125
 - Malarone™ 715
 - Manual of Patent Examining Procedure (MPEP) 725
 - market exclusivities, protect branded drugs 691–695
 - marketing authorization (MA) 530, 692
 - material transfer agreement (MTA) 739, 740
 - mathematical modeling and simulation (M&S)
 - diseases 434
 - pharmacokinetics (PK) to pharmacodynamics 434
 - PK-PDDZ, drug action 434
 - translational pharmacology 436
 - maximal tolerated dose (MTD) 449, 512
 - maximum daily dose (MDD) 232, 235
 - melt emulsion method 342, 344–346, 358, 359
 - membrane transporters 182–183
 - merger and/or acquisition (M&A) 745
 - mesenchymal–epithelial transition factor (MET) 443–445, 447
 - metabolic engineering 73
 - meta*-chlorobenzoate 159
 - 3-methylcholanthrene (3MC) 607, 608
 - MET– models 442–449
 - Michaelis–Menten elimination 443
 - microbial hydroxylation, of steroids 76
 - micronucleated TK6 cells 590
 - micronucleus testing (MNT) 589–591
 - microtubule aggregate 585–589, 591, 592, 597
 - mitochondrial toxicity 505–506
 - Miyaura borylation 97
 - MK-7655 (relebactam) 484
 - modified Irwin test 534
 - molecularly targeted agents (MTAs)
 - dose-dependent ER relationships 436, 439
 - drug discovery and development of 435
 - in vivo* antitumor efficacy 434
 - in vivo* drug potency of 436
 - PK-PDDZ relationships 436
 - PKDZ relationships 441
 - translational pharmacology 435
 - monetization of patents 672–673
 - Monte Carlo (MC) simulations 415, 425, 426, 475
 - multi-column continuous (MCC) chromatography 54
 - multidrug resistance (MDR) 183, 184
 - multidrug resistance-associated protein 2 (MRP2) transporter 184
 - multistage continuous processing 104, 109–110
 - mustard route 126, 129–133, 135, 141
 - mutual acceptance of data (MAD) 514
 - Mycobacterium marinum* (mCAR) 87
 - Mycobacterium smegmatis* (MsAcT) 88
- n**
- N*-acetylgalactosamine (GalNAc) 504
 - Naïve Bayes classification algorithm 556
 - N*-alkylation/arylation 82

- nanonization 178
 - National Environmental Policy Act (NEPA) of 1969 550
 - Nernst–Brunner variation 176, 290
 - neuroblastoma cells (SK-N-BE) 584
 - new active substances (NAS) 256
 - new chemical entity (NCE) 49, 314, 527
 - FiH 312–326
 - preclinical formulation selection 305–312
 - predicting preclinical formulation performance 308–312
 - new drug application (NDA) 205, 256, 657, 660, 696, 723, 744
 - new molecular entities (NMEs) 212, 433
 - new single step biotransformations
 - chemical catalysis
 - catalytic C–C bond formation 92
 - heteroatom arylation 90
 - IRED 83
 - process scale consideration 94–96
 - nicotinic acid 250, 373
 - N*-methylmorpholine (NMM) 156
 - nocodazole 585–589, 591–593
 - nonclinical evaluation of potential for
 - delayed ventricular repolarization 508, 529, 533
 - nonclinical safety pharmacology 541
 - formalization of 528
 - regulatory framework 529
 - nondisclosure agreements (NDAs) 721, 727
 - non-patent exclusivities
 - new chemical entity 660–661
 - new clinical study 661–552
 - non-ribosomal methods 88
 - no-observed-adverse-effect-level (NOAEL) approach 13, 316, 377, 390, 502, 508, 515, 516, 551, 638, 639
 - Noyes–Whitney equation 176, 220
 - Noyes–Whitney/Nernst–Brunner equation 290
 - nuclear magnetic resonance (NMR) spectroscopy 25, 137, 240
 - Nuremberg Code 527
- O**
- Øie-Tozer method 411
 - ω -transaminase/acyltransferase 88
 - ω -transaminase (ω -ATA) 81
 - oral bioavailability
 - definition 412
 - in vivo* based prediction 413
 - prediction of 414
 - ordered Zhang scores 592
 - organic anion transporter peptide (OATP) 185
 - Organisation for Economic Co-operation and Development (OECD)
 - principles 514, 570
 - quality standard 514
 - orphan drug exclusivity 663–666
 - osteosarcoma cells (U2OS) 585
 - Ostwald–Freundlich equation (OFE) 290
 - Ostwald ripening 161, 290, 340, 342–346, 350, 355–359
 - 4-oxalocrotonate tautomerase (4-OT) 89
- P**
- parallel artificial membrane
 - permeability assay (PAMPA) 311
 - Parikh–Doering conditions 141
 - particle size distribution (PSD) 24, 220, 248, 272–276, 281, 282, 286, 288, 292, 347
 - particle size reduction
 - analytical techniques 278, 280, 281, 283
 - bioavailability 290–291
 - bottom-up techniques 275
 - desired particle size 291–294
 - in early drug development 294–296
 - flow charts 288
 - instrument model 278
 - nanosized crystalline particles
 - commercial product benefits 297–299

- emerging nanoparticle techniques 300–301
- nanoparticles and targeting
 - delivery 299–300
- on-line techniques 279
- particle size method goals 288
- questions and possible goals 288
- regulatory and quality considerations 276–277
- scanning techniques 284
- set of techniques 278–289
- size and sampling 278
- spherical beads 286
- strategic plans and risk management 271
- top-down techniques 274
- particle size, of compound 178
- particle size techniques 277–278
- partitioning coefficient (Log *P*) 177
- partner pharmaceutical company 743
- passive diffusion 171, 180–182, 405, 408
- passive transcellular transport 181
- patent
 - cliff 697
 - correcting issued patents 687
 - limitations, broadening claims 687
 - limitations, in damages 688
 - monetization 672
 - publication of research 681
 - purpose of 650
 - requirements, for patent protection
 - enablement 654
 - non-obviousness 653–654
 - novelty 653
 - subject matter 652
 - utility 652–653
 - term and scope 651
 - types of 650–651
- patentability
 - invention 670
 - subject matter eligible for, patent protection 668
- patent applications
 - amendments and arguments 683
 - anticipation, infringement and validity 683
 - continuation-in-part applications (CIP) 685
 - continuous applications 684
 - divisional applications 686
 - invention, prior art 681
 - patent claim construction 682
 - patent specification 682
- Patent Cooperation Treaty (PCT) 679, 680, 737
- patent exclusivities
 - regulatory approval 660
 - USPTO approval, delays 660
- patent infringement 256, 654–656, 658, 662, 693, 694, 698–700, 702, 713–717, 721, 722, 724, 742, 743
- patent law 6, 649–666, 686, 687, 723, 728, 732, 738
- patent portfolio
 - API 674–675
 - dosage and treatment methods 676–677
 - first vs. second generation drugs 673–674
 - formulations 675–676
 - manufacturing methods 677
 - prior art drugs 678
 - protection of commercial products and exclusive rights 671–672
 - variation and development 677–678
- patent protection 6, 649–654, 658, 667–689, 694, 695, 704–707, 709, 710, 713, 718, 722, 723, 725, 727, 737, 742
- patent term extension 660, 711, 712, 718, 744
- patheon 47
- patient information leaflet (PIL) 694
- P450 catalysed carbene reactions 86
- pediatric exclusivity 664–666
- peptide transporter 1 (PEPT1) 184, 185
- peptidomimetic pharmacological agents 185
- P-Glycoprotein (P-gp) 183–184, 402, 446, 474, 506
- pharmacodynamic analyses 637–638

- pharmacokinetic/pharmacodynamic (PK/PD)
 - communication across discipline
 - cross-functional communication
 - misconceptions 389–392
 - integrated thinking 392–395
 - in vitro* vs. *in vivo* perspective 392
 - concentration-response relationship
 - chronic indications 378–382
 - dose-scheduling 377–378
 - equilibrium concentration 374
 - human clinical effects 374
 - in vivo* concentration-response relationship 374, 376
 - nonmonotonous concentration-response curves 375–377
 - pharmacological response 374
 - in vivo* response-time course 369
 - target biology
 - biomarker to monitor 372
 - buffering, tolerance, and redundancy 372
 - data patterns 370
 - drug discovery phase 369
 - experimental design 373
 - experimental model and protocol 373
 - pattern recognition 370
 - physiological context 371–372
 - species and translation 374
 - target vs. off-target/confounding factors 372
 - treatment vs. cure 374
 - time-delays 374–382
 - temporal differences
 - drug concentration-response patterns 382, 384
 - models of time delays 385
 - pharmacological response *in time order* 382
 - translational impact
 - drug candidates 387–388
 - drug delivery to target biology 385–387
 - system and drug properties 389
- pharmacokinetic/pharmacodynamic (PKPD) 468, 625
- pharmacokinetic-pharmacodynamic-disease (PK-PDDZ)
 - clinical development 460
 - M&S approach
 - drug discovery and development 434
 - PKDZ model 440
 - PK Model 437
 - PKPD Modeling 438
- pharmacokinetic-target engagement (PK-TE) 473
- phosphopantetheinyl transferase (PPase) 87
- photo-decomplexation 129
- photodegradation rate 203
- phototoxicity 501, 508–509, 514
- physiologically-based pharmacokinetic (PBPK) models 415, 470, 568
- P450 induction 613
- PK and PKPD predictions 400, 416–421, 425
- plug-flow reactors (PFR) 27
- polycyclic aromatic hydrocarbons (PAHs) 611
- polymorphism 204–206, 243, 356, 503, 634
- polymorph screening 65
 - aqueous and organic solubility 208
 - chemical stability and purity 208–209
 - form and thermal properties 208
 - form selection and desired properties 206, 207
 - hygroscopicity 208
 - methods of 209
 - relative stability 211
- polyvinylpyrrolidone (PVP) 341
- positron emission tomography (PET) 135, 473, 516
- potential structure activity relationship 592–594
- powder in capsule (PIC) formulation
 - clinical data analysis methodology 315–318
 - clinical doses 320
 - clinical performance 314
 - clinical success 320

- permeability values 318–326
 - physicochemical characteristics 318–326
 - solubility values 318–326
 - powder X-ray diffraction (PXRD) 26, 245
 - precipitation method 341, 343–346, 358
 - preclinical lead profile (PLP) 36
 - pre-clinical toxicology evaluation
 - clinical trial 516–517
 - compound safety assessment 504–513
 - drug toxicity development program 501, 502
 - GLP toxicology 513–515
 - phase I clinical trials 517
 - target safety assessment 500–504
 - predicted human dose 399, 477, 616, 626
 - predicting human pharmacokinetics
 - clinical drug candidate molecule 401
 - experimental data 401–402
 - predicting Clearance 402–410
 - predicting pharmacokinetics (PK) profiles
 - one compartment model 415
 - PBPK models 415–416
 - plasma concentration-time profiles 415
 - target patient population 416
 - predictive dissolution technology 312
 - predictive toxicology 550–553, 555, 556, 559, 560, 567, 569, 571, 582
 - pregnane X receptor (PXR) 607
 - preparative chromatography 27, 53–55, 59
 - primary pharmacology 472, 499, 500, 507, 527, 530, 531, 534
 - process analytical technology (PAT) 23, 248
 - process development, technologies
 - biocatalysis 74
 - continuous chemistry
 - biphasic reaction 106
 - electrochemistry 108–109
 - high temperature and pressure 105–106
 - photochemistry 107–108
 - safety 106–107
 - single stage continuous processing 104
 - continuous processing 103
 - fast reactions, unstable intermediates 104–105
 - process scale consideration 94
 - synthetic biochemistry 76
 - fermentation technology 76
 - retrosynthetic steps 77
 - process induced transformations 252, 253
 - progression-free survival (PFS) 442
 - proof-of-concept (POC) 14, 43, 164, 271, 313, 418, 435, 459, 468, 482, 596
 - proof of mechanism (POM) 15, 418, 435
 - proprotein convertase subtilisin/kexin type 9 (PCSK9) 503
 - prosecution costs 737–738
 - proton pump inhibitors (PPI) 371, 706
 - protoveratrine alkaloids 32
 - proven acceptable ranges (PARs) 69
 - provisional and nonprovisional patent applications 679
 - pulmonary arterial hypertension (PAH) 665
 - pyridoxal 5'-phosphate (PLP) 89
- q**
- qualified infectious disease product (QIDP) 692
 - quality by design (QbD) paradigm 569
 - quality control (QC) 59, 74, 113, 206, 275, 569
 - quantitative high-throughput screening (qHTS) techniques 581
 - quantitative pharmacology (QP) 390, 416
 - quantitative structure transcription assay relationships (QSTAR) 582

r

- random forest (RF) 552
 - Rapamune® 297
 - rat *in vivo* induction protocol 618–619
 - rate of absorption 258, 291, 316, 317, 401, 413, 414
 - raw material (RM) 18, 20, 27, 38, 49, 53, 62, 63, 76
 - (2'R) -2'-deoxy-2'-C-methyl uridine 147, 149
 - recommended phase II dose (RP2D) 449, 639
 - regulatory starting material (RSM) 66
 - regulatory toxicology/Reg-Tox 12, 28, 305
 - relative population doubling (RPD) 594
 - renal plasma clearance 407
 - renal safety pharmacology 541
 - research agreement
 - death and divorce 745–746
 - dispute resolution provisions 735
 - enforcement costs 738–739
 - FTO analysis 727
 - indemnification 739
 - modified toy design of invention 726
 - NDA's 727
 - ownership 732
 - prosecution costs 737–738
 - public announcements and publications 730–732
 - scope of collaboration 728–729
 - sharing technology 739–742
 - toy design 726
 - trade secrets 729–730
 - U.S.C. § 102(c) states 725
 - written collaborative agreement 725
 - ring closing metathesis (RCM) 113
 - robust in-process controls (IPCs) 65
- s**
- safety benefits, against cancer-selective pathways
 - cancer selectivity mechanism 633
 - efficacy and safety 636
 - therapeutic potential, *ex vivo* studies 636–637
 - toxicity 631
 - safety pharmacology
 - definition 527
 - discovery and candidate selection 530–532
 - first-in-human studies 532–541
 - cardiovascular system 536
 - ICH S7A 532, 533
 - ICH S7B 533
 - objectives 533–534
 - principles 534
 - historical background 528–529
 - nonclinical 541
 - objectives for 528, 533–534
 - SAFT-gamma software 307
 - salt and cocrystal
 - API process 229
 - case study
 - atorvastatin 258
 - indinavir 257
 - complex dosage forms 249
 - crystalline forms 230
 - crystalline salts 229
 - early dosage form 249
 - formulation processes 252
 - large scale 248
 - regulatory aspects 255
 - screening
 - computational approaches 238
 - counterions and cofomers 231
 - early development stage 230
 - fit-for-purpose study 230
 - late phase development 231
 - manual vs. automated 236
 - polymorph 241
 - workflow 240
 - selection 242
 - small scale (multiple gram) process 247
 - salt formation 159, 164, 229, 232, 239, 240, 353
 - salt screening 65–66, 239, 240
 - scaling of clearance 408–410
 - Schlenk techniques 134

- secondary pharmacology 501, 505,
 507–508, 527, 528, 534
 serotonin transporter (SERT) 125
 sertraline 54, 211, 707
Silicibacter pomeroyi 88
 simulated intestinal fluid (SIF) 174,
 252, 253, 311, 315
 simulated moving bed (SMB)
 chromatography 54
 single stage continuous processing 104
 Sirius Inform™ equipment 310
 SLC transporters 183
 slurry bridging 210, 211
 (*S*)-naproxen 106
 sodium dodecyl sulfate (SDS) 283, 341
 solid dosage forms 203, 218–220, 275,
 299, 313
 solid form manipulation 305
 solid form selection 159–161, 206, 212
 solid phase extraction (SPE) 55
 Solid-State Chemistry Information
 (SSCI) 205
 solid-state properties
 amorphous solid dispersions
 defined 213
 dissolution and stability issue 214
 drug product 213
 HME 214
 spray drying 213
 workflow 214
 crystalline states
 hydrates 205
 polymorphism 205, 206
 salts and cocrystals 206
 solvates 205
 drug substance 203, 215
 form selection process 212
 physical form 203
 polymorph screening 206
 solubility 175
 and dissolution rate 177
 solubility-permeability interplay
 cyclodextrin-based formulations
 186
 oral biopharmaceutics 185
 oral drug absorption 185
 solubilization, cosolvents 186
 sonocrystallization 275, 276
 S1P₁ agonists 623
 specialized technology groups,
 API 21
 sphingosine-1-phosphate (S1P)
 receptor 603
 AhR binding and CYP1A induction
 615
 arylhydrocarbon receptor
 activation 607–609
 CYP1A enzyme family 612–613
 CYP1A induction, AhR 611–612
 CYP1A (auto) induction, non-rodent
 species 609
 human AhR agonist assay 623
 iterative experimentation 622
 lead optimization programme 603
 minimising cardiovascular safety risk
 624
 positioning dose, lead optimization
 625
 preclinical safety
 DDI liability 605
 toxicogenomics use 607
 spontaneously hypertensive rat (SHR)
 32
 spray-drying 161, 164, 213–214, 241,
 249, 275, 276, 291, 341
 stem cell-based genotoxicity assay 582
 stereoselectivity 149, 155, 156
 strategy modification, lead optimisation
 CYP1A induction in human systems
 615, 619
 induction screening, rat hepatocytes
 618
Streptomyces 83, 87, 297
 structure-activity relationship (SAR)
 33, 126, 232, 511, 517, 557, 582,
 592–594, 611
 summary of product characteristics
 (SmPC) 694
 supercritical fluid chromatography
 (SFC) 55
 supplementary protection certificate
 (SPC) 700, 711
 sustainable manufacturing 75
 Suzuki reactions 64, 75, 90, 113

- Suzuki–Miyaura cross-coupling strategy
17, 128, 135
- Synthesis Management Team (SMT)
15
- synthetic biochemistry 75–90, 111,
113
- synthetic biology 74, 89, 90
- t**
- TAK-020 (Takeda) cocrystal 229
- Takeda Pharmaceuticals 476
- target engagement (TE) level 472
- target product profile (TPP) 2, 3, 626
- target safety assessment 500–504
- terazosin hydrochloride (Hytrin[®]) 239
- tetrabutylammonium sulfate (TBAS)
157
- 2,3,7,8-tetrachlorodibenzo-*p*-dioxin
(TCDD) (dioxin) 611
- therapeutic dose predictions 400,
418
- thermal gravimetric analysis (TGA)
161, 245
- thin-layer chromatography (TLC) 65
- thorough quantitative thinking (TQT)
392, 568
- toxicogenomic approaches 509
- toxicokinetic-toxicodynamic (TK/TD)
approaches 6
- Toxtree 558, 564, 566
- trade secrets 20, 668, 721, 724,
727–730
- TRAIL pathway
activate using small molecule 634
cancer therapeutic strategy 632
therapeutic engagement 634
- TRAIL-Inducing Compounds (TICs)
635–636
- transaminase-catalyzed preparation, of
sitagliptin 82
- transcriptional profiling, to capture
polypharmacology 583
- Translational Pharmaceuticals[®] 47
- translational pharmacology
antibacterials 483
anti-inflammation 489
diabetes 476
in vitro and animal models 468
neuroscience
MK-1 472–474
PK-TE relationship 474
PKPD model 468, 469, 472, 473,
475
plan 470
translational PKPD model 472
transmissible spongiform
encephalopathies (TSE) 78
Trintellix[®] 125, 126
tumor growth inhibition/regression
(TGI) 436
tumor necrosis factor-related
apoptosis-inducing ligand
(TRAIL) 631
tyrosine kinase inhibitors (TKIs)
first-in-human 433
in vivo PK-PDDZ relationships 435
M&S approaches 434
MTAs 433
translational pharmacology for
434–436
- u**
- ultra-high performance liquid
chromatography (UPLC) 25
- ultrasonic crystallization method 341,
346–347
- Unified Patent Court (UPC) 699
- United States Patent and Trademark
Office (USPTO) 649, 738
- United States Pharmacopeia (USP)
174, 215, 277, 285
- unpatentable natural law 669
- unspecific peroxygenases (UPOs) 84
- unstirred water layer (UWL) 182
- U2OS cells 586
- upregulation of genes 608
- uridine protection, impurities 151
- U.S. Federal Food, Drug and Cosmetic
Act (FDCA) 656
- U.S. Food and Drug Administration
(FDA) 125, 174, 657
- U.S. patent system 649, 650, 670,
691–694, 704–706, 709, 710, 712,
718, 722, 723

V

- Viagra™ 665, 697, 706
- vinblastine 183, 587, 588, 590–592
- Visitor's Confidentiality Agreement (VCA) 733
- volume of distribution 338, 381, 401, 407, 410–412, 424, 437, 474, 604, 606
- volume of fluids 179
- vortioxetine
 - metabolites of
 - mono-hydroxylated 137–139
 - N-oxidation 135
 - synthesis of
 - iron-mediated synthetic route 128, 129
 - mustard route 129
 - palladium-mediated route 132

- parallel chemistry 131
- radioligand synthesis 135

W

- wet milling method 348–350
 - Wittig reaction 149, 152
 - women of childbearing potential (WOCB) 517
 - World Health Organization (WHO) 174
 - World Intellectual Property Organization (WIPO) 723
 - written collaborative agreement 725
-
- X**
 - X-linked inhibitor of apoptosis protein (XIAP) 633

